Learn

There have been a number of clinical trials evaluating novel therapies in patients with heart failure that have led to recent updates of international heart failure guidelines. Given that the 2018 National Heart Foundation of Australia (NHFA) and Cardiac Society of Australia and New Zealand (CSANZ) heart failure guidelines were not scheduled for review and the high level of clinician interest, an academic group (Evidence to Practice) facilitated a working group comprising clinicians with expertise in the diagnosis and management of heart failure in Australia to develop a consensus statement focusing on studies evaluating new and established drugs to prevent or treat heart failure, published since the 2018 guidelines.

This MJA consensus statement shares more.

Details